Table 1 Patient (n=44) and tumour (n=45) characteristics

From: Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL

 

n (%)

Sex

 Male

19 (43)

 Female

25 (57)

Age (years), median (range)

65.5 (36–87)

Risk classification

 Very low risk

4 (9)

 Low risk

13 (29)

 Intermediate risk

13 (29)

 High risk

15 (33)

Primary site

 Stomach

29 (64)

 Small intestine

12 (27)

 Colon

3 (7)

 Unknown

1 (2)

Histology

 Spindle cell

37 (82)

 Epithelioid

7 (16)

 Mixed

1 (2)

Tumour size

 ⩽5 cm

19 (42)

 5–10 cm

17 (38)

 >10 cm

9 (20)

Mitotic figures

 ⩽5 per 50 HPF

38 (84)

 >5 per 50 HPF

7 (16)

KIT mutation

 Exon 11 mutation

28 (62)

 Exon 9 mutation

1 (2)

 No exon 11 or 9 mutation

15 (33)

 Unknown

1 (2)

  1. Abbreviation: HPF=high power fields.